Ajay S. Behl, PhD


CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Ajay V. Maker, MD, FACS


New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

Ajjai Shivaram Alva, MBBS


Dr. Alva on the Shift Toward Combination Therapy in mRCC

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Aju Mathew, MD, MPhil


Staying Afloat When the Floodgates Open

It is quite easy to be drowned in the rising floodwaters of hematology and medical oncology, especially when you start training.

Akash Patnaik, MD, PhD


Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Akhil Kumar, MD


Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review

In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.

Akihiko Shimomura, MD, PhD


Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast Cancer

Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.

Akshat Jain, MD, MPH’15


International Hematology/Oncology Elective: A Unique Learning Experience

Although minor institution-specific variations exist, traditional fellowship programs in the United States are able to provide training in the sophisticated Western style of practice.

Akshjot Puri, MD


Dr. Puri on Challenges With Treating Older Patients With Pancreatic Cancer

Akshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.

Al B. Benson, MD


Dr. Benson on the Complexity of Up-front Treatment in HCC

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

Alain Algazi, MD


Dr. Algazi on Benefit of Continuous Dabrafenib/Trametinib Dosing in BRAF+ Melanoma

Alain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.

Alain C. Mita, MD


Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

Alan D. Winkler, MHSA, FACMPE


Practice in South Texas Offers Vertically Integrated Cancer Care

Providing comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.

Alan Dove, PhD


Healthcare IT Still Seeks a Security Blanket

August has traditionally been a sleepy month for government regulatory agencies, but this year, Washington's usual summer torpor was interrupted by a rush of new initiatives, as more than three-quarters of a trillion dollars from the American Recovery and Reinvestment Act surged into a mind- boggling range of projects.

Alan H. Bryce, MD, Mayo Clinic


nmCRPC: Clinical Trial Data on AR Inhibitors

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Alan M. Miller, MD, PhD


Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid Leukemia

One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.

Alan P. Venook, MD


Dr. Venook on the Unmet Need Addressed by The GALAXY Trial Examining ctDNA in CRC

Alan P. Venook, MD, discusses the unmet need addressed by the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Alan Pollack, MD, PhD


A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Alan Sandler, MD


Dr. Sandler on Immunotherapies to Treat Lung Cancer

Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer

Alan Shain, PhD


Expert Discusses Mutations in Melanoma

Alan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.

Alan Skarbnik, MD


Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCL

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Alan T. Blank, MD, MS


3-D Printing Technology Enhances Limb Preservation in Cancer Operations

Limb preservation is now the procedure of choice for the treatment of patients with bone cancer.